nodes	percent_of_prediction	percent_of_DWPC	metapath
Ganciclovir—SLC22A7—Methotrexate—esophageal cancer	0.275	0.491	CbGbCtD
Ganciclovir—SLC22A8—Methotrexate—esophageal cancer	0.168	0.3	CbGbCtD
Ganciclovir—SLC22A6—Methotrexate—esophageal cancer	0.117	0.209	CbGbCtD
Ganciclovir—Valaciclovir—SLC10A2—esophageal cancer	0.0114	0.522	CrCbGaD
Ganciclovir—Aciclovir—SLC10A2—esophageal cancer	0.0105	0.478	CrCbGaD
Ganciclovir—Mood swings—Capecitabine—esophageal cancer	0.000818	0.00196	CcSEcCtD
Ganciclovir—Ataxia—Capecitabine—esophageal cancer	0.000812	0.00194	CcSEcCtD
Ganciclovir—Coma—Methotrexate—esophageal cancer	0.000809	0.00194	CcSEcCtD
Ganciclovir—Blood creatinine increased—Capecitabine—esophageal cancer	0.000809	0.00194	CcSEcCtD
Ganciclovir—Dehydration—Capecitabine—esophageal cancer	0.000803	0.00192	CcSEcCtD
Ganciclovir—Mouth ulceration—Methotrexate—esophageal cancer	0.000801	0.00192	CcSEcCtD
Ganciclovir—Urinary tract disorder—Cisplatin—esophageal cancer	0.0008	0.00191	CcSEcCtD
Ganciclovir—Liver function test abnormal—Capecitabine—esophageal cancer	0.000797	0.00191	CcSEcCtD
Ganciclovir—Connective tissue disorder—Cisplatin—esophageal cancer	0.000796	0.00191	CcSEcCtD
Ganciclovir—Urethral disorder—Cisplatin—esophageal cancer	0.000794	0.0019	CcSEcCtD
Ganciclovir—Dry skin—Capecitabine—esophageal cancer	0.000791	0.00189	CcSEcCtD
Ganciclovir—Hypokalaemia—Capecitabine—esophageal cancer	0.000786	0.00188	CcSEcCtD
Ganciclovir—Visual impairment—Cisplatin—esophageal cancer	0.000781	0.00187	CcSEcCtD
Ganciclovir—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000778	0.00186	CcSEcCtD
Ganciclovir—Nasopharyngitis—Capecitabine—esophageal cancer	0.000772	0.00185	CcSEcCtD
Ganciclovir—Sepsis—Methotrexate—esophageal cancer	0.000768	0.00184	CcSEcCtD
Ganciclovir—Gastritis—Capecitabine—esophageal cancer	0.000764	0.00183	CcSEcCtD
Ganciclovir—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000762	0.00182	CcSEcCtD
Ganciclovir—Muscular weakness—Capecitabine—esophageal cancer	0.000762	0.00182	CcSEcCtD
Ganciclovir—Tinnitus—Cisplatin—esophageal cancer	0.000756	0.00181	CcSEcCtD
Ganciclovir—Lymphadenopathy—Methotrexate—esophageal cancer	0.000753	0.0018	CcSEcCtD
Ganciclovir—Abdominal distension—Capecitabine—esophageal cancer	0.000751	0.0018	CcSEcCtD
Ganciclovir—Dysphagia—Capecitabine—esophageal cancer	0.000746	0.00179	CcSEcCtD
Ganciclovir—Thrombophlebitis—Methotrexate—esophageal cancer	0.000743	0.00178	CcSEcCtD
Ganciclovir—Bronchospasm—Capecitabine—esophageal cancer	0.000734	0.00176	CcSEcCtD
Ganciclovir—Mediastinal disorder—Cisplatin—esophageal cancer	0.00073	0.00175	CcSEcCtD
Ganciclovir—Arrhythmia—Cisplatin—esophageal cancer	0.000724	0.00173	CcSEcCtD
Ganciclovir—Alopecia—Cisplatin—esophageal cancer	0.000716	0.00171	CcSEcCtD
Ganciclovir—Hepatic failure—Methotrexate—esophageal cancer	0.000715	0.00171	CcSEcCtD
Ganciclovir—Pancytopenia—Capecitabine—esophageal cancer	0.000709	0.0017	CcSEcCtD
Ganciclovir—Malnutrition—Cisplatin—esophageal cancer	0.000705	0.00169	CcSEcCtD
Ganciclovir—Dysuria—Capecitabine—esophageal cancer	0.000698	0.00167	CcSEcCtD
Ganciclovir—Neutropenia—Capecitabine—esophageal cancer	0.000698	0.00167	CcSEcCtD
Ganciclovir—Renal failure acute—Methotrexate—esophageal cancer	0.000696	0.00167	CcSEcCtD
Ganciclovir—Flatulence—Cisplatin—esophageal cancer	0.000695	0.00166	CcSEcCtD
Ganciclovir—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000694	0.00166	CcSEcCtD
Ganciclovir—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000681	0.00163	CcSEcCtD
Ganciclovir—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000681	0.00163	CcSEcCtD
Ganciclovir—Muscle spasms—Cisplatin—esophageal cancer	0.000678	0.00162	CcSEcCtD
Ganciclovir—Weight decreased—Capecitabine—esophageal cancer	0.000675	0.00162	CcSEcCtD
Ganciclovir—Hyperglycaemia—Capecitabine—esophageal cancer	0.000673	0.00161	CcSEcCtD
Ganciclovir—Pneumonia—Capecitabine—esophageal cancer	0.000669	0.0016	CcSEcCtD
Ganciclovir—Infestation NOS—Capecitabine—esophageal cancer	0.000665	0.00159	CcSEcCtD
Ganciclovir—Infestation—Capecitabine—esophageal cancer	0.000665	0.00159	CcSEcCtD
Ganciclovir—Vision blurred—Cisplatin—esophageal cancer	0.000665	0.00159	CcSEcCtD
Ganciclovir—Tremor—Cisplatin—esophageal cancer	0.000661	0.00158	CcSEcCtD
Ganciclovir—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00066	0.00158	CcSEcCtD
Ganciclovir—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000656	0.00157	CcSEcCtD
Ganciclovir—Ill-defined disorder—Cisplatin—esophageal cancer	0.000655	0.00157	CcSEcCtD
Ganciclovir—Renal failure—Capecitabine—esophageal cancer	0.000654	0.00156	CcSEcCtD
Ganciclovir—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000652	0.00156	CcSEcCtD
Ganciclovir—Anaemia—Cisplatin—esophageal cancer	0.000652	0.00156	CcSEcCtD
Ganciclovir—Stomatitis—Capecitabine—esophageal cancer	0.000649	0.00155	CcSEcCtD
Ganciclovir—Jaundice—Capecitabine—esophageal cancer	0.000649	0.00155	CcSEcCtD
Ganciclovir—Conjunctivitis—Capecitabine—esophageal cancer	0.000647	0.00155	CcSEcCtD
Ganciclovir—Urinary tract infection—Capecitabine—esophageal cancer	0.000647	0.00155	CcSEcCtD
Ganciclovir—Malaise—Cisplatin—esophageal cancer	0.000636	0.00152	CcSEcCtD
Ganciclovir—Haematuria—Capecitabine—esophageal cancer	0.000634	0.00152	CcSEcCtD
Ganciclovir—Leukopenia—Cisplatin—esophageal cancer	0.000631	0.00151	CcSEcCtD
Ganciclovir—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000629	0.00151	CcSEcCtD
Ganciclovir—Agranulocytosis—Capecitabine—esophageal cancer	0.000621	0.00149	CcSEcCtD
Ganciclovir—Irritability—Methotrexate—esophageal cancer	0.000614	0.00147	CcSEcCtD
Ganciclovir—Convulsion—Cisplatin—esophageal cancer	0.000611	0.00146	CcSEcCtD
Ganciclovir—Mood swings—Methotrexate—esophageal cancer	0.000609	0.00146	CcSEcCtD
Ganciclovir—Ataxia—Methotrexate—esophageal cancer	0.000604	0.00145	CcSEcCtD
Ganciclovir—Myalgia—Cisplatin—esophageal cancer	0.000601	0.00144	CcSEcCtD
Ganciclovir—Haemoglobin—Capecitabine—esophageal cancer	0.0006	0.00144	CcSEcCtD
Ganciclovir—Rhinitis—Capecitabine—esophageal cancer	0.000599	0.00143	CcSEcCtD
Ganciclovir—Anxiety—Cisplatin—esophageal cancer	0.000599	0.00143	CcSEcCtD
Ganciclovir—Haemorrhage—Capecitabine—esophageal cancer	0.000597	0.00143	CcSEcCtD
Ganciclovir—Hepatitis—Capecitabine—esophageal cancer	0.000597	0.00143	CcSEcCtD
Ganciclovir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000596	0.00143	CcSEcCtD
Ganciclovir—Hypoaesthesia—Capecitabine—esophageal cancer	0.000594	0.00142	CcSEcCtD
Ganciclovir—Liver function test abnormal—Methotrexate—esophageal cancer	0.000593	0.00142	CcSEcCtD
Ganciclovir—Discomfort—Cisplatin—esophageal cancer	0.000593	0.00142	CcSEcCtD
Ganciclovir—Pharyngitis—Capecitabine—esophageal cancer	0.000593	0.00142	CcSEcCtD
Ganciclovir—Urinary tract disorder—Capecitabine—esophageal cancer	0.00059	0.00141	CcSEcCtD
Ganciclovir—Oedema peripheral—Capecitabine—esophageal cancer	0.000588	0.00141	CcSEcCtD
Ganciclovir—Connective tissue disorder—Capecitabine—esophageal cancer	0.000587	0.0014	CcSEcCtD
Ganciclovir—Urethral disorder—Capecitabine—esophageal cancer	0.000586	0.0014	CcSEcCtD
Ganciclovir—Anaphylactic shock—Cisplatin—esophageal cancer	0.000576	0.00138	CcSEcCtD
Ganciclovir—Oedema—Cisplatin—esophageal cancer	0.000576	0.00138	CcSEcCtD
Ganciclovir—Visual impairment—Capecitabine—esophageal cancer	0.000576	0.00138	CcSEcCtD
Ganciclovir—Infection—Cisplatin—esophageal cancer	0.000572	0.00137	CcSEcCtD
Ganciclovir—Erythema multiforme—Capecitabine—esophageal cancer	0.000565	0.00135	CcSEcCtD
Ganciclovir—Thrombocytopenia—Cisplatin—esophageal cancer	0.000564	0.00135	CcSEcCtD
Ganciclovir—Tachycardia—Cisplatin—esophageal cancer	0.000562	0.00134	CcSEcCtD
Ganciclovir—Skin disorder—Cisplatin—esophageal cancer	0.000559	0.00134	CcSEcCtD
Ganciclovir—Tinnitus—Capecitabine—esophageal cancer	0.000557	0.00133	CcSEcCtD
Ganciclovir—Hyperhidrosis—Cisplatin—esophageal cancer	0.000557	0.00133	CcSEcCtD
Ganciclovir—Eosinophilia—Methotrexate—esophageal cancer	0.00055	0.00132	CcSEcCtD
Ganciclovir—Anorexia—Cisplatin—esophageal cancer	0.000549	0.00131	CcSEcCtD
Ganciclovir—Pancreatitis—Methotrexate—esophageal cancer	0.000545	0.0013	CcSEcCtD
Ganciclovir—Angiopathy—Capecitabine—esophageal cancer	0.000542	0.0013	CcSEcCtD
Ganciclovir—Mediastinal disorder—Capecitabine—esophageal cancer	0.000538	0.00129	CcSEcCtD
Ganciclovir—Hypotension—Cisplatin—esophageal cancer	0.000538	0.00129	CcSEcCtD
Ganciclovir—Chills—Capecitabine—esophageal cancer	0.000536	0.00128	CcSEcCtD
Ganciclovir—Arrhythmia—Capecitabine—esophageal cancer	0.000534	0.00128	CcSEcCtD
Ganciclovir—Alopecia—Capecitabine—esophageal cancer	0.000528	0.00126	CcSEcCtD
Ganciclovir—Pancytopenia—Methotrexate—esophageal cancer	0.000528	0.00126	CcSEcCtD
Ganciclovir—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000525	0.00125	CcSEcCtD
Ganciclovir—Mental disorder—Capecitabine—esophageal cancer	0.000523	0.00125	CcSEcCtD
Ganciclovir—Malnutrition—Capecitabine—esophageal cancer	0.00052	0.00124	CcSEcCtD
Ganciclovir—Dysuria—Methotrexate—esophageal cancer	0.00052	0.00124	CcSEcCtD
Ganciclovir—Neutropenia—Methotrexate—esophageal cancer	0.00052	0.00124	CcSEcCtD
Ganciclovir—Paraesthesia—Cisplatin—esophageal cancer	0.000517	0.00124	CcSEcCtD
Ganciclovir—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000516	0.00124	CcSEcCtD
Ganciclovir—Dyspnoea—Cisplatin—esophageal cancer	0.000513	0.00123	CcSEcCtD
Ganciclovir—Flatulence—Capecitabine—esophageal cancer	0.000512	0.00123	CcSEcCtD
Ganciclovir—Erectile dysfunction—Methotrexate—esophageal cancer	0.000512	0.00122	CcSEcCtD
Ganciclovir—Dysgeusia—Capecitabine—esophageal cancer	0.000509	0.00122	CcSEcCtD
Ganciclovir—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000507	0.00121	CcSEcCtD
Ganciclovir—Back pain—Capecitabine—esophageal cancer	0.000503	0.0012	CcSEcCtD
Ganciclovir—Decreased appetite—Cisplatin—esophageal cancer	0.0005	0.0012	CcSEcCtD
Ganciclovir—Muscle spasms—Capecitabine—esophageal cancer	0.0005	0.0012	CcSEcCtD
Ganciclovir—Pneumonia—Methotrexate—esophageal cancer	0.000498	0.00119	CcSEcCtD
Ganciclovir—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000497	0.00119	CcSEcCtD
Ganciclovir—Infestation NOS—Methotrexate—esophageal cancer	0.000495	0.00119	CcSEcCtD
Ganciclovir—Infestation—Methotrexate—esophageal cancer	0.000495	0.00119	CcSEcCtD
Ganciclovir—Pain—Cisplatin—esophageal cancer	0.000492	0.00118	CcSEcCtD
Ganciclovir—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000491	0.00117	CcSEcCtD
Ganciclovir—Vision blurred—Capecitabine—esophageal cancer	0.00049	0.00117	CcSEcCtD
Ganciclovir—Tremor—Capecitabine—esophageal cancer	0.000487	0.00117	CcSEcCtD
Ganciclovir—Renal failure—Methotrexate—esophageal cancer	0.000487	0.00116	CcSEcCtD
Ganciclovir—Stomatitis—Methotrexate—esophageal cancer	0.000483	0.00116	CcSEcCtD
Ganciclovir—Ill-defined disorder—Capecitabine—esophageal cancer	0.000482	0.00115	CcSEcCtD
Ganciclovir—Conjunctivitis—Methotrexate—esophageal cancer	0.000482	0.00115	CcSEcCtD
Ganciclovir—Anaemia—Capecitabine—esophageal cancer	0.000481	0.00115	CcSEcCtD
Ganciclovir—Sweating—Methotrexate—esophageal cancer	0.000475	0.00114	CcSEcCtD
Ganciclovir—Feeling abnormal—Cisplatin—esophageal cancer	0.000474	0.00114	CcSEcCtD
Ganciclovir—Haematuria—Methotrexate—esophageal cancer	0.000472	0.00113	CcSEcCtD
Ganciclovir—Malaise—Capecitabine—esophageal cancer	0.000469	0.00112	CcSEcCtD
Ganciclovir—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000468	0.00112	CcSEcCtD
Ganciclovir—Vertigo—Capecitabine—esophageal cancer	0.000467	0.00112	CcSEcCtD
Ganciclovir—Leukopenia—Capecitabine—esophageal cancer	0.000465	0.00111	CcSEcCtD
Ganciclovir—Agranulocytosis—Methotrexate—esophageal cancer	0.000462	0.00111	CcSEcCtD
Ganciclovir—Body temperature increased—Cisplatin—esophageal cancer	0.000455	0.00109	CcSEcCtD
Ganciclovir—Cough—Capecitabine—esophageal cancer	0.000454	0.00109	CcSEcCtD
Ganciclovir—Hypertension—Capecitabine—esophageal cancer	0.000449	0.00107	CcSEcCtD
Ganciclovir—Haemoglobin—Methotrexate—esophageal cancer	0.000447	0.00107	CcSEcCtD
Ganciclovir—Haemorrhage—Methotrexate—esophageal cancer	0.000445	0.00106	CcSEcCtD
Ganciclovir—Hepatitis—Methotrexate—esophageal cancer	0.000445	0.00106	CcSEcCtD
Ganciclovir—Arthralgia—Capecitabine—esophageal cancer	0.000443	0.00106	CcSEcCtD
Ganciclovir—Chest pain—Capecitabine—esophageal cancer	0.000443	0.00106	CcSEcCtD
Ganciclovir—Myalgia—Capecitabine—esophageal cancer	0.000443	0.00106	CcSEcCtD
Ganciclovir—Pharyngitis—Methotrexate—esophageal cancer	0.000441	0.00106	CcSEcCtD
Ganciclovir—Anxiety—Capecitabine—esophageal cancer	0.000441	0.00106	CcSEcCtD
Ganciclovir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00044	0.00105	CcSEcCtD
Ganciclovir—Urinary tract disorder—Methotrexate—esophageal cancer	0.000439	0.00105	CcSEcCtD
Ganciclovir—Discomfort—Capecitabine—esophageal cancer	0.000437	0.00105	CcSEcCtD
Ganciclovir—Urethral disorder—Methotrexate—esophageal cancer	0.000436	0.00104	CcSEcCtD
Ganciclovir—Dry mouth—Capecitabine—esophageal cancer	0.000433	0.00104	CcSEcCtD
Ganciclovir—Visual impairment—Methotrexate—esophageal cancer	0.000429	0.00103	CcSEcCtD
Ganciclovir—Confusional state—Capecitabine—esophageal cancer	0.000428	0.00102	CcSEcCtD
Ganciclovir—Oedema—Capecitabine—esophageal cancer	0.000424	0.00102	CcSEcCtD
Ganciclovir—Hypersensitivity—Cisplatin—esophageal cancer	0.000424	0.00101	CcSEcCtD
Ganciclovir—Infection—Capecitabine—esophageal cancer	0.000422	0.00101	CcSEcCtD
Ganciclovir—Erythema multiforme—Methotrexate—esophageal cancer	0.00042	0.00101	CcSEcCtD
Ganciclovir—Thrombocytopenia—Capecitabine—esophageal cancer	0.000416	0.000994	CcSEcCtD
Ganciclovir—Tinnitus—Methotrexate—esophageal cancer	0.000415	0.000992	CcSEcCtD
Ganciclovir—Tachycardia—Capecitabine—esophageal cancer	0.000414	0.000991	CcSEcCtD
Ganciclovir—Asthenia—Cisplatin—esophageal cancer	0.000413	0.000988	CcSEcCtD
Ganciclovir—Skin disorder—Capecitabine—esophageal cancer	0.000412	0.000986	CcSEcCtD
Ganciclovir—Hyperhidrosis—Capecitabine—esophageal cancer	0.00041	0.000982	CcSEcCtD
Ganciclovir—Anorexia—Capecitabine—esophageal cancer	0.000405	0.000968	CcSEcCtD
Ganciclovir—Angiopathy—Methotrexate—esophageal cancer	0.000403	0.000965	CcSEcCtD
Ganciclovir—Mediastinal disorder—Methotrexate—esophageal cancer	0.000401	0.000959	CcSEcCtD
Ganciclovir—Chills—Methotrexate—esophageal cancer	0.000399	0.000955	CcSEcCtD
Ganciclovir—Hypotension—Capecitabine—esophageal cancer	0.000397	0.000949	CcSEcCtD
Ganciclovir—Diarrhoea—Cisplatin—esophageal cancer	0.000394	0.000942	CcSEcCtD
Ganciclovir—Alopecia—Methotrexate—esophageal cancer	0.000393	0.00094	CcSEcCtD
Ganciclovir—Mental disorder—Methotrexate—esophageal cancer	0.00039	0.000932	CcSEcCtD
Ganciclovir—Malnutrition—Methotrexate—esophageal cancer	0.000387	0.000926	CcSEcCtD
Ganciclovir—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000387	0.000925	CcSEcCtD
Ganciclovir—Insomnia—Capecitabine—esophageal cancer	0.000384	0.000918	CcSEcCtD
Ganciclovir—Paraesthesia—Capecitabine—esophageal cancer	0.000381	0.000912	CcSEcCtD
Ganciclovir—Dysgeusia—Methotrexate—esophageal cancer	0.000379	0.000907	CcSEcCtD
Ganciclovir—Dyspnoea—Capecitabine—esophageal cancer	0.000378	0.000905	CcSEcCtD
Ganciclovir—Back pain—Methotrexate—esophageal cancer	0.000374	0.000896	CcSEcCtD
Ganciclovir—Dyspepsia—Capecitabine—esophageal cancer	0.000374	0.000894	CcSEcCtD
Ganciclovir—Decreased appetite—Capecitabine—esophageal cancer	0.000369	0.000883	CcSEcCtD
Ganciclovir—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000366	0.000877	CcSEcCtD
Ganciclovir—Vomiting—Cisplatin—esophageal cancer	0.000366	0.000876	CcSEcCtD
Ganciclovir—Fatigue—Capecitabine—esophageal cancer	0.000366	0.000875	CcSEcCtD
Ganciclovir—Vision blurred—Methotrexate—esophageal cancer	0.000365	0.000873	CcSEcCtD
Ganciclovir—Rash—Cisplatin—esophageal cancer	0.000363	0.000868	CcSEcCtD
Ganciclovir—Pain—Capecitabine—esophageal cancer	0.000363	0.000868	CcSEcCtD
Ganciclovir—Constipation—Capecitabine—esophageal cancer	0.000363	0.000868	CcSEcCtD
Ganciclovir—Dermatitis—Cisplatin—esophageal cancer	0.000363	0.000868	CcSEcCtD
Ganciclovir—Ill-defined disorder—Methotrexate—esophageal cancer	0.000359	0.000859	CcSEcCtD
Ganciclovir—Anaemia—Methotrexate—esophageal cancer	0.000358	0.000856	CcSEcCtD
Ganciclovir—Feeling abnormal—Capecitabine—esophageal cancer	0.00035	0.000837	CcSEcCtD
Ganciclovir—Malaise—Methotrexate—esophageal cancer	0.000349	0.000835	CcSEcCtD
Ganciclovir—Vertigo—Methotrexate—esophageal cancer	0.000348	0.000832	CcSEcCtD
Ganciclovir—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000347	0.00083	CcSEcCtD
Ganciclovir—Leukopenia—Methotrexate—esophageal cancer	0.000347	0.000829	CcSEcCtD
Ganciclovir—Nausea—Cisplatin—esophageal cancer	0.000342	0.000818	CcSEcCtD
Ganciclovir—Cough—Methotrexate—esophageal cancer	0.000338	0.000808	CcSEcCtD
Ganciclovir—Urticaria—Capecitabine—esophageal cancer	0.000337	0.000807	CcSEcCtD
Ganciclovir—Abdominal pain—Capecitabine—esophageal cancer	0.000335	0.000803	CcSEcCtD
Ganciclovir—Body temperature increased—Capecitabine—esophageal cancer	0.000335	0.000803	CcSEcCtD
Ganciclovir—Convulsion—Methotrexate—esophageal cancer	0.000335	0.000802	CcSEcCtD
Ganciclovir—Myalgia—Methotrexate—esophageal cancer	0.00033	0.000788	CcSEcCtD
Ganciclovir—Arthralgia—Methotrexate—esophageal cancer	0.00033	0.000788	CcSEcCtD
Ganciclovir—Chest pain—Methotrexate—esophageal cancer	0.00033	0.000788	CcSEcCtD
Ganciclovir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000327	0.000783	CcSEcCtD
Ganciclovir—Discomfort—Methotrexate—esophageal cancer	0.000326	0.000779	CcSEcCtD
Ganciclovir—Confusional state—Methotrexate—esophageal cancer	0.000319	0.000762	CcSEcCtD
Ganciclovir—Anaphylactic shock—Methotrexate—esophageal cancer	0.000316	0.000756	CcSEcCtD
Ganciclovir—Infection—Methotrexate—esophageal cancer	0.000314	0.000751	CcSEcCtD
Ganciclovir—Hypersensitivity—Capecitabine—esophageal cancer	0.000313	0.000748	CcSEcCtD
Ganciclovir—Thrombocytopenia—Methotrexate—esophageal cancer	0.000309	0.00074	CcSEcCtD
Ganciclovir—Skin disorder—Methotrexate—esophageal cancer	0.000307	0.000734	CcSEcCtD
Ganciclovir—Hyperhidrosis—Methotrexate—esophageal cancer	0.000305	0.000731	CcSEcCtD
Ganciclovir—Asthenia—Capecitabine—esophageal cancer	0.000304	0.000728	CcSEcCtD
Ganciclovir—Anorexia—Methotrexate—esophageal cancer	0.000301	0.00072	CcSEcCtD
Ganciclovir—Pruritus—Capecitabine—esophageal cancer	0.0003	0.000718	CcSEcCtD
Ganciclovir—Hypotension—Methotrexate—esophageal cancer	0.000295	0.000706	CcSEcCtD
Ganciclovir—Diarrhoea—Capecitabine—esophageal cancer	0.00029	0.000695	CcSEcCtD
Ganciclovir—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000288	0.000689	CcSEcCtD
Ganciclovir—Insomnia—Methotrexate—esophageal cancer	0.000286	0.000684	CcSEcCtD
Ganciclovir—Paraesthesia—Methotrexate—esophageal cancer	0.000284	0.000679	CcSEcCtD
Ganciclovir—Dyspnoea—Methotrexate—esophageal cancer	0.000282	0.000674	CcSEcCtD
Ganciclovir—Somnolence—Methotrexate—esophageal cancer	0.000281	0.000672	CcSEcCtD
Ganciclovir—Dizziness—Capecitabine—esophageal cancer	0.000281	0.000671	CcSEcCtD
Ganciclovir—Dyspepsia—Methotrexate—esophageal cancer	0.000278	0.000665	CcSEcCtD
Ganciclovir—Decreased appetite—Methotrexate—esophageal cancer	0.000275	0.000657	CcSEcCtD
Ganciclovir—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000273	0.000653	CcSEcCtD
Ganciclovir—Fatigue—Methotrexate—esophageal cancer	0.000272	0.000652	CcSEcCtD
Ganciclovir—Pain—Methotrexate—esophageal cancer	0.00027	0.000646	CcSEcCtD
Ganciclovir—Vomiting—Capecitabine—esophageal cancer	0.00027	0.000646	CcSEcCtD
Ganciclovir—Rash—Capecitabine—esophageal cancer	0.000268	0.00064	CcSEcCtD
Ganciclovir—Dermatitis—Capecitabine—esophageal cancer	0.000267	0.00064	CcSEcCtD
Ganciclovir—Headache—Capecitabine—esophageal cancer	0.000266	0.000636	CcSEcCtD
Ganciclovir—Feeling abnormal—Methotrexate—esophageal cancer	0.00026	0.000623	CcSEcCtD
Ganciclovir—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000258	0.000618	CcSEcCtD
Ganciclovir—Nausea—Capecitabine—esophageal cancer	0.000252	0.000603	CcSEcCtD
Ganciclovir—Urticaria—Methotrexate—esophageal cancer	0.000251	0.0006	CcSEcCtD
Ganciclovir—Abdominal pain—Methotrexate—esophageal cancer	0.00025	0.000598	CcSEcCtD
Ganciclovir—Body temperature increased—Methotrexate—esophageal cancer	0.00025	0.000598	CcSEcCtD
Ganciclovir—Hypersensitivity—Methotrexate—esophageal cancer	0.000233	0.000557	CcSEcCtD
Ganciclovir—Asthenia—Methotrexate—esophageal cancer	0.000227	0.000542	CcSEcCtD
Ganciclovir—Pruritus—Methotrexate—esophageal cancer	0.000224	0.000535	CcSEcCtD
Ganciclovir—Diarrhoea—Methotrexate—esophageal cancer	0.000216	0.000517	CcSEcCtD
Ganciclovir—Dizziness—Methotrexate—esophageal cancer	0.000209	0.0005	CcSEcCtD
Ganciclovir—Vomiting—Methotrexate—esophageal cancer	0.000201	0.000481	CcSEcCtD
Ganciclovir—Rash—Methotrexate—esophageal cancer	0.000199	0.000477	CcSEcCtD
Ganciclovir—Dermatitis—Methotrexate—esophageal cancer	0.000199	0.000476	CcSEcCtD
Ganciclovir—Headache—Methotrexate—esophageal cancer	0.000198	0.000474	CcSEcCtD
Ganciclovir—Nausea—Methotrexate—esophageal cancer	0.000188	0.000449	CcSEcCtD
